CD8A and neoplasm: While checkpoint inhibitor therapy is a novel approach in B-cell lymphomas, there are several parameters that may impair the efficacy of this approach, including impaired antigen recognition by anti-tumor CD8+ T-cells through loss or reduced expression of MHC class I and II components, including beta 2 microglobulin, defects in IFN signaling pathways, and loss of HLA heterozygosity among other patient-intrinsic factors.